| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae84948901b77f34fd51c41264d8d19c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4523 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-397
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate |
2006-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f09a1aacc22f133d49ad22e315ad83b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7deccb40cf1e0edcda9bf217271f8d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d1978751489f3a13d0d4e73beebb3f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_164b684e0ad81fc91f7c29f5c62d4cd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f73c8d851c8be62e6e0aae5a0c58ff0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a0678f4abe7860df8e982b5e1444b23 |
| publicationDate |
2006-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NO-20061966-L |
| titleOfInvention |
Bicyclo [3.1.1.] Heptane-substituted benzimidazolone and quinazolinone derivatives as agonists for human ORL1 receptors |
| abstract |
This invention relates to a group of hydronopoly substituted benzimidazolone and quinazolinone derivatives which are agonists of human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel benzimidazolone and the quinazolinone derivatives as an active ingredient, as well as the use of these pharmaceutical compositions for the treatment of disorders involving ORL1 receptors. Where the symbols have the meanings given in the description. The invention relates to compounds of the general formula (1) |
| priorityDate |
2003-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |